Moreover, based on TCGA cohort, IGF2BP3 showed significantly up-regulated in both intestinal- and diffuse- types of GC when compared with normal control (P < 0.001, Fig. 1e). This evidence concerns the gene IGF2BP3 and gastric cancer.